{"groups":[{"description":"Ramucirumab (10 milligram/kilogram \\[mg/kg\\]) intravenously (IV) plus docetaxel (75 milligram/square meter \\[mg/m²\\]) IV on day 1 of each 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.","id":"FG000","title":"Ramucirumab + Docetaxel"},{"description":"Placebo IV plus docetaxel (75 mg/m²) IV on day 1 of each 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.","id":"FG001","title":"Placebo + Docetaxel"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"14"},{"groupId":"FG001","numSubjects":"12"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"13"},{"groupId":"FG001","numSubjects":"14"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"185"},{"groupId":"FG001","numSubjects":"200"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"2"}],"type":"Randomized, But Never Treated"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"263"},{"groupId":"FG001","numSubjects":"267"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"258"},{"groupId":"FG001","numSubjects":"265"}],"type":"Received at Least One Dose of Study Drug"},{"achievements":[{"groupId":"FG000","numSubjects":"46"},{"groupId":"FG001","numSubjects":"39"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"217"},{"groupId":"FG001","numSubjects":"228"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Completers include participants who are confirmed to be alive at study completion."}